Skip to main content
. 2021 May;9(10):867. doi: 10.21037/atm-21-1606

Figure 3.

Figure 3

Representative radiochromatograms of human samples from four subjects after oral dosing of 110 mg/50 µCi [14C] almonertinib: (A) pooled human plasma 6 hours, (B) pooled urine samples 0–96 hours, and (C) pooled feces samples 0–240 hours, respectively.